Back to Press Releases Medtronic Pump Receives Best of 2003 Award

Deanne McLaughlin
Medtronic MiniMed
(818) 576-4325
Rachael Scherer
Medtronic, Inc.
(763) 505-2694

F O R   I M M E D I A T E   R E L E A S E

Medtronic's Intelligent Insulin Pump System Chosen By Popular Science Magazine To Receive A 2003 "Best Of What's New" Award

- Innovative insulin pump system is recognized as one of this country's top 100 innovations -

NORTHRIDGE, Calif., Nov. 7, 2003 - For years, diabetes patients had to perform complex "diabetes math" and manually inject insulin to keep their blood sugar levels within a safe range. Now, an "intelligent" insulin pump performs this math and recommends proper insulin dosages to help improve health and extend life. This innovative system, which also incorporates wireless technology to automatically transmit a blood sugar value from a glucose monitor to the pump, has been chosen by Popular Science magazine to receive a 2003 "Best of What's New" Award in the personal health category.

Chosen after the evaluation of thousands of products, the Paradigm® 512 Insulin Pump and Paradigm LinkTM Blood Glucose Monitor system is among 100 winners being featured in Popular Science magazine's December issue, due on newsstands Nov.12.

Introduced in July 2003, the Paradigm 512 system has been well received by patients and physicians for its integrated insulin dosing support, which can both enhance and simplify insulin therapy. By eliminating the guesswork and simplifying diabetes management, it's anticipated that more patients and physicians will find it easier to adopt pump therapy. In fact, anyone who uses insulin to treat diabetes might benefit from this important therapy.

Without the help of the Paradigm 512 pump's Bolus WizardTM calculator, managing diabetes is a more complex process. Patients using insulin must consider their current and target blood glucose levels, current carbohydrate intake, insulin sensitivity factor, and insulin-to-carbohydrate ratio when mentally calculating an insulin dosage. This task can be difficult, particularly since these targets, sensitivities and ratios change throughout the day. Even more difficult is estimating the amount of insulin remaining in the body from prior insulin injections. Knowing how much insulin is "active" in the body is important in preventing dangerous episodes of low blood sugar. The Paradigm 512 system does all of this, precisely, at the touch of a few buttons.

"We are very pleased Popular Science has recognized our integrated pump system for its significant technological advancement in diabetes management," said Jeffery A. McCaulley, vice president and general manager of Medtronic's Diabetes business. "We have known for some time that an insulin pump can more closely mimic a healthy pancreas. Now we have harnessed advanced insulin pump technology with insulin dosing support, making it easier for anyone using insulin to achieve good blood sugar control."

The system's insulin pump is developed and manufactured by Medtronic's Diabetes business, Medtronic MiniMed, and the Paradigm LinkTM Blood Glucose Monitor is co-developed with, and manufactured by, the BD Diabetes Care Unit of BD Medical (Becton, Dickinson and Company) (NYSE: BDX). The Paradigm Link monitor is powered by BD LogicTM Technology. "The power of glucose monitoring and the benefits of insulin pump therapy are combined in a patient-friendly system that can further simplify and improve diabetes care," said Gary Cohen, president, BD Medical.

Medtronic recently introduced the Paradigm 712 insulin pump system, which has the same user-friendly features as the Paradigm 512 insulin pump. The new Paradigm 712 pump holds a larger three-milliliter (3 ml) reservoir, making the pump well suited for people who use more than 50 units of insulin per day. Diabetes patients who require more insulin include children, young adults, insulin-resistant Type 1 and Type 2 patients, and women with gestational diabetes.

More than 1 million Americans are afflicted with type 1 diabetes, and another 3 million type 2 diabetes patients are estimated to use insulin to control blood sugar levels, improve their health and attain a better quality of life. High and low blood sugar fluctuations can cause loss of consciousness or even death, as well as long-term complications such as blindness, kidney failure, amputation, impotence and heart disease. For many patients, managing diabetes is difficult without the use of an insulin pump and frequent blood glucose monitoring.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.

Medtronic's Diabetes business ( designs, develops, manufactures and markets advanced infusion systems with a primary emphasis on the intensive management of diabetes. The company's products include external pumps, related disposables, and a continuous glucose monitoring system. Medtronic, Inc. (, headquartered in Minneapolis, is the world's leading medical technology company, providing lifelong solutions for people with chronic disease. Additional information about the Paradigm 512 insulin pump and the Paradigm Link monitor is available online at

- 0 -

EDITOR'S NOTE: Detailed information about diabetes, insulin pump therapy and the Paradigm 512 pump and Paradigm Link system is available by accessing Medtronic's online newsroom at

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding either company's performance, including future revenues, products and income, or events or developments that either company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; either company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in either company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in healthcare or other governmental regulation, as well as other factors discussed in this press release and in each respective company's most recent Form 10-K and subsequent filings made with the Securities and Exchange Commission. Neither company intends to update any forward-looking statements.

  Home Return to Top

Last Updated: Wednesday November 05, 2014 21:27:33
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.